Hosted in Chicago from July 29 to 31, the 77th ADLM Annual Conference & Clinical Lab Expo brought together global thought leaders in clinical laboratory science and healthcare innovation. Committed to R&D of IVD and life science products, BIOELAB connected with attending specialists for academic and commercial dialogue to advance its global expansion plan.
With more than 70 years of history, ADLM is the world’s most prestigious and largest annual event for clinical diagnostics. The show annually gathers over 800 exhibitors, nearly 10,000 professional attendees and 250+ academic symposia, serving as a core hub for latest technologies and innovative industry concepts.
Technology Drives Comprehensive IVD Product Refresh
A well-established IVD manufacturer with 15 years of dedicated R&D, BIOELAB showcased its upgraded instrument lineup and new product portfolio during ADLM 2025.
· Auto Hematology Analyzer: Available in 3-diff and 5-diff configurations, designed for microvolume blood testing. Compact footprint, intuitive operation and low maintenance cost fit all types of laboratory settings.
· BT-330 Auto Chemistry Analyzer: Optional ISE module configurable; maximum throughput up to 490 tests/hour with consistent running stability and high efficiency, ideal routine lab equipment.
· IA200 Fully Auto CLIA Analyzer (Our first in-house developed model): Supports onboard reagent replacement and continuous sample loading. Built with multi-round magnetic separation & washing plus high-efficiency B/F separation to cover full-range clinical test demands.
· CL-600 Auto Coagulation Analyzer: Features proprietary dynamic light source enhancement technology that auto-selects optimal detection wavelength based on specimen conditions, delivering strong anti-interference performance and high sensitivity. Its pull-out rack design allows inline consumable loading without system downtime to improve lab workflow efficiency.
Facing continuously evolving global clinical challenges, BIOELAB persistently increases R&D spending to pioneer cutting-edge IVD technologies. Each technical upgrade moves us closer to more precise, efficient and user-friendly in vitro diagnostic solutions.
Exploring New Insights, Promoting Joint Development
BIOELAB’s booth remained busy throughout the expo. Our onsite team held in-depth technical and business discussions with worldwide clients and industry counterparts.Aside from securing new prospective partners, we gained positive acknowledgment from long-term customers for reliable product quality and all-round after-sales support, establishing solid groundwork for future R&D iteration and regional market expansion.
Advancing Together, Striving for New Win-Win Growth
After years of international market development, BIOELAB’s products are sold to over 80 countries across five continents with total installed base exceeding 60,000 units. Backed by superior core technologies and full-lifecycle service, BIOELAB has built solid brand reputation across North America and global IVD marketplace.
Going forward, BIOELAB will continue to contribute to the development of the global IVD industry with professionalism and innovation. Next stop: Germany! We look forward to meeting you in Düsseldorf to jointly fuel innovative vitality and driving force for the global healthcare industry.
